Headquartered in Guangzhou, China, and established in 2014, Burning Rock Biotech Limited is primarily engaged in developing and providing diagnostic solutions for ...
Burning Rock Biotech Limited (NASDAQ: BNR) is a precision oncology diagnostics company headquartered in Guangzhou, China, founded in 2014. The company positions itself as an NGS-based “cancer therapy selection” platform, supporting clinical decision-making by analyzing tumor samples to identify actionable biomarkers, predict prognosis, and improve matching between patients and targeted ...Burning Rock Biotech Limited (NASDAQ: BNR) is a precision oncology diagnostics company headquartered in Guangzhou, China, founded in 2014. The company positions itself as an NGS-based “cancer therapy selection” platform, supporting clinical decision-making by analyzing tumor samples to identify actionable biomarkers, predict prognosis, and improve matching between patients and targeted therapies.
Business model and operations are organized around three operating segments described in the source: (1) Central Laboratory Business, where samples are processed in centralized lab settings; (2) In-Hospital Business, which integrates diagnostic testing into hospital delivery and patient care workflows; and (3) Pharma Research and Development Services, where Burning Rock supports biopharma partners through testing and research activities tied to clinical trials and drug development.
Products and services revolve around NGS-based tests that can be performed using both tissue and liquid biopsy samples. The company’s flagship offerings highlighted in the provided description include OncoCompass IO (a liquid biopsy test), OncoScreen IO (a comprehensive pan-cancer tissue test), and OncoCompass Target (a ctDNA liquid biopsy test focused on non-small cell lung cancer). For gastrointestinal cancers and specific biomarker needs, it offers ColonCore (microsatellite instability and mutation-related assessment). In oncology areas related to homologous recombination deficiency, it provides OncoScreen ParpMatch and OncoCompass ParpMatch tests. These products are designed to cover multiple cancer types including lung, gastrointestinal, prostate, breast, lymphomas, thyroid, colorectal, ovarian, pancreatic, and bladder cancers.
From a commercialization and partner perspective, Burning Rock has entered strategic arrangements intended to expand test offerings and market reach. The provided description includes a development/commercialization license with Myriad Genetics for Myriad myChoice tumor testing in China, and a licensing agreement with Oncocyte Corporation for DetermaRx, a risk stratification test for early-stage lung cancer, also for the Chinese market. In addition, the company collaborates with pharmaceutical and biotech partners (examples cited in the source include AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, and Merck KGaA) through clinical trials and research studies.
Cost and BOM considerations for an NGS diagnostics company generally include reagents (sequencing library prep), consumables, sample processing logistics, bioinformatics, and personnel/lab overhead; however, the provided dataset does not break out cost-of-goods or BOM explicitly. Financially, the available FMP snapshot shows a small market capitalization figure on the order of tens of millions of USD (market cap ~11.2M USD), a beta around 1.38 (higher volatility profile), and profitability pressures at the snapshot date (negative operating/net margins and negative free cash flow yields). The dataset also shows strong gross margin (reported gross profit margin ~0.746) alongside negative operating/earnings metrics, which suggests the revenue base may be supported by high gross profitability but offset by operating and R&D expenses. Liquidity metrics provided (e.g., current ratio ~3.05 and quick ratio ~2.81) indicate the company has maintained substantial working-capital coverage.
Key people include Yusheng Han, who is identified in the sources as the founder, chairman of the board, and chief executive officer. The company’s described mission is “Guard Life via Science,” reflecting an emphasis on translating genomics/NGS insights into clinically actionable diagnostics. In terms of “wishes” or strategic direction, its partnership activity and broad test portfolio suggest ongoing efforts to deepen biomarker coverage, expand adoption across institutions, and strengthen alliances with global and regional biopharma companies through co-development and licensed testing programs.
EPS estimate unavailable · Fiscal period ending 2026-06-30
D-10
5Y Trend (Revenue, Earnings, FCF)
Metric
Latest
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$539.6M
+4.6%
-14.5%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-55.3M
+84.0%
-13.6%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
+74.7%
+6.3%
-7.4%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
-10.2%
+85.3%
-83.2%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
-10.3%
+84.7%
-32.9%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-33.7M
+65.7%
-264.7%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
-6.2%
+67.2%
-292.8%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
8.1%
-10.6%
+22.3%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
2.99x
+2.5%
+2.0%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
